Episode Details
Back to Episodes
Siren Dumps Ascendis, Ascends to New Heights
Description
Siren sold its entire stake in Ascendis Pharma, netting $52.87 million, as Ascendis reported a strong first quarter with revenue doubling to €247 million, driven by YORVIPATH and SKYTROFA. Ascendis added over 1,000 new U.S. patients for YORVIPATH and launched YUVIWEL, achieving a profit of €629 million. Despite Ascendis success, Sirens sale suggests a potential cooling of expectations, with investors watching for steady cash flow in the pipeline.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/c1068e65cc4825b1